Combined Immune Therapy for the Treatment of Visceral Leishmaniasis

PLoS Neglected Tropical Diseases

Volumn 10, Issue 2, 2016, Pages

  Faleiro, Rebecca J ^a,b   Kumar, Rajiv ^a,c,d   Bunn, Patrick T ^a,e   Singh, Neetu ^d   Chauhan, Shashi Bhushan ^d   Sheel, Meru ^a   Amante, Fiona H ^a   Montes de Oca, Marcela ^a,f   Edwards, Chelsea L ^a,f   Ng, Susanna S ^a,e   Best, Shannon E ^a   Haque, Ashraful ^a   Beattie, Lynette ^a   Hafner, Louise M ^b   Sacks, David ^g   Nylen, Susanne ^h   Sundar, Shyam ^d   Engwerda, Christian R ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c NETAJI SUBHAS INSTITUTE OF TECHNOLOGY   (India)

^d BANARAS HINDU UNIVERSITY   (India)

^e GRIFFITH UNIVERSITY   (Australia)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; INTERLEUKIN 10 RECEPTOR; CYTOKINE; INTERLEUKIN 10;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PARASITE IMMUNITY; PERIPHERAL BLOOD MONONUCLEAR CELL; REAL TIME POLYMERASE CHAIN REACTION; SPLEEN CELL; VISCERAL LEISHMANIASIS; ANIMAL; C57BL MOUSE; IMMUNOLOGY; IMMUNOTHERAPY; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PARASITOLOGY; PHYSIOLOGY; SPLEEN; TH1 CELL;

ANIMALS; CYTOKINES; FEMALE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-10; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; MICE; MICE, INBRED C57BL; SPLEEN; TH1 CELLS;

EID: 84959463948     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004415     Document Type: Article

References (58)

1. Sharma P, Allison JP, (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell161: 205–214. doi: 10.1016/j.cell.2015.03.03025860605
2. Sharma P, Allison JP, (2015) The future of immune checkpoint therapy. Science348: 56–61. doi: 10.1126/science.aaa817225838373
3. Melero I, Grimaldi AM, Perez-Gracia JL, Ascierto PA, (2013) Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res19: 997–1008. doi: 10.1158/1078-0432.CCR-12-221423460531
4. Naidoo J, Page DB, Wolchok JD, (2014) Immune modulation for cancer therapy. Br J Cancer111: 2214–2219. doi: 10.1038/bjc.2014.34825211661
5. Pardoll DM, (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer12: 252–264. doi: 10.1038/nrc323922437870
6. Engwerda CR, Ng SS, Bunn PT, (2014) The Regulation of CD4(+) T Cell Responses during Protozoan Infections. Front Immunol5: 498. doi: 10.3389/fimmu.2014.0049825352846
7. Faleiro RJ, Kumar R, Hafner LM, Engwerda CR, (2014) Immune regulation during chronic visceral leishmaniasis. PLoS Negl Trop Dis8: e2914. doi: 10.1371/journal.pntd.000291425010815
8. Boelaert M, Sundar S, Farrer J, Hotez PJ, Junghanss T, Kang G, Lalloo D, (2014) Leishmaniasis. In: et al., editors. Manson'd Tropical Diseases. Amsterdam: Elsevier. pp. 631–651.
9. Bankoti R, Stäger S, (2012) Differential regulation of the immune response in the spleen and liver of mice infected with Leishmania donovani. Journal of Tropical Medicine 2012.
10. Stanley A, Engwerda C, (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunology and Cell Biology85: 138–147. 17146466
11. Bucheton B, Kheir M, El-Safi S, Hammad A, Mergani A, et al. (2002) The interplay between environmental and host factors during an outbreak of visceral leishmaniasis in eastern Sudan. Microbes and Infection4: 1449–1457. 12475635
12. Ho M, Siongok T, Lyerly W, Smith D, (1982) Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene76: 741–746. 6984547
13. Sacks D, Lal S, Shrivastava S, Blackwell J, Neva F, (1987) An analysis of T cell responsiveness in Indian kala-azar. The Journal of Immunology138: 908–913. 3100620
14. Sundar S, Chakravarty J, (2013) Leishmaniasis: an update of current pharmacotherapy. Expert Opinion on Pharmacotherapy14: 53–63. doi: 10.1517/14656566.2013.75551523256501
15. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW, (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med362: 504–512. doi: 10.1056/NEJMoa090362720147716
16. Sundar S, Sinha P, Rai M, Verma D, Nawin K, et al. (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. The Lancet377: 477–486.
17. Gautam S, Kumar R, Maurya R, Nylen S, Ansari N, et al. (2011) IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis204: 1134–1137. doi: 10.1093/infdis/jir46121881130
18. Nylén S, Maurya R, Eidsmo L, Manandhar K, Sundar S, et al. (2007) Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. The Journal of Experimental Medicine204: 805–817. 17389235
19. Saraiva M, O'Garra A, (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol10: 170–181. doi: 10.1038/nri271120154735
20. Kumar R, Singh N, Gautam S, Singh OP, Gidwani K, et al. (2014) Leishmania specific CD4 T cells release IFNgamma that limits parasite replication in patients with visceral leishmaniasis. PLoS Negl Trop Dis8: e3198. doi: 10.1371/journal.pntd.000319825275531
21. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA, (2013) Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function. J Immunol191: 5542–5550. doi: 10.4049/jimmunol.130181024154626
22. Murphy M, Cotterell S, Gorak P, Engwerda C, Kaye P, (1998) Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. The Journal of Immunology161: 4153–4160. 9780188
23. Zubairi S, Sanos SL, Hill S, Kaye PM, (2004) Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur J Immunol34: 1433–1440. 15114677
24. Martin S, Agarwal R, Murugaiyan G, Saha B, (2010) CD40 expression levels modulate regulatory T cells in Leishmania donovani infection. J Immunol185: 551–559. doi: 10.4049/jimmunol.090220620525887
25. Mathur RK, Awasthi A, Wadhone P, Ramanamurthy B, Saha B, (2004) Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat Med10: 540–544. 15107845
26. Murray HW, (2005) Prevention of relapse after chemotherapy in a chronic intracellular infection: mechanisms in experimental visceral leishmaniasis. J Immunol174: 4916–4923. 15814719
27. Rosas L, Satoskar A, Roth K, Keiser T, Barbi J, et al. (2006) Interleukin-27R (WSX-1/T-Cell Cytokine Receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. The American Journal of Pathology168: 158–169. 16400019
28. Gantt K, Schultz-Cherry S, Rodriguez N, Jeronimo S, Nascimento E, et al. (2003) Activation of TGF-β by Leishmania chagasi: Importance for Parasite Survival in Macrophages. The Journal of Immunology170: 2613–2620. 12594289
29. Haque A, Stanley AC, Amante FH, Rivera Fde L, Zhou Y, et al. (2010) Therapeutic glucocorticoid-induced TNF receptor-mediated amplification of CD4+ T cell responses enhances antiparasitic immunity. J Immunol184: 2583–2592. doi: 10.4049/jimmunol.090308020139272
30. Rosenzweig M, Ponte J, Apostolou I, Doty D, Guild J, et al. (2010) Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR. ASCO Meeting Abstracts28: e13028.
31. Ansari NA, Kumar R, Gautam S, Nylen S, Singh OP, et al. (2011) IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol186: 3977–3985. doi: 10.4049/jimmunol.100358821357266
32. Bunn PT, Stanley AC, de Labastida Rivera F, Mulherin A, Sheel M, et al. (2014) Tissue requirements for establishing long-term CD4+ T cell-mediated immunity following Leishmania donovani infection. J Immunol192: 3709–3718. doi: 10.4049/jimmunol.130076824634490
33. Stanley A, Zhou Y, Amante F, Randall L, Haque A, et al. (2008) Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog4: e1000028. doi: 10.1371/journal.ppat.100002818463695
34. Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, et al. (2005) Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med202: 885–891. 16186187
35. O'Farrell AM, Liu Y, Moore KW, Mui AL, (1998) IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways. EMBO J17: 1006–1018. 9463379
36. Murray HW, Montelibano C, Peterson R, Sypek JP, (2000) Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J Infect Dis182: 1497–1502. 11023473
37. Stanley AC, de Labastida Rivera F, Haque A, Shee M, Zhou Y, et al. (2011) Critical roles for LIGHT and its receptors in generating T cell-mediated immunity during Leishmania donovani infection. PLoS Pathogens7: e1002279. doi: 10.1371/journal.ppat.100227921998581
38. Stanley A, Dalton J, Rossotti S, MacDonald K, Zhou Y, et al. (2008) VCAM-1 and VLA-4 modulate dendritic cell IL-12p40 production in experimental visceral leishmaniasis. PLoS Pathog4: e1000158. doi: 10.1371/journal.ppat.100015818802456
39. Murphy M, Wille U, Villegas E, Hunter C, Farrell J, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. European Journal of Immunology31: 2848–2856. 11592059
40. Murray H, Lu C, Mauze S, Freeman S, Moreira A, et al. (2002) Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infection and Immunity70: 6284–6293. 12379707
41. Murray H, Stern J, Welte K, Rubin B, Carriero S, et al. (1987) Experimental visceral leishmaniasis: Production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. The Journal of Immunology138: 2290–2297. 3104456
42. Henson SM, Akbar AN, (2009) KLRG1—more than a marker for T cell senescence. Age (Dordr)31: 285–291.
43. Voehringer D, Koschella M, Pircher H, (2002) Lack of proliferative capacity of human effector and memory T cells expressing killer cell lectinlike receptor G1 (KLRG1). Blood100: 3698–3702. 12393723
44. Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, et al. (2013) T cell responses: naive to memory and everything in between. Adv Physiol Educ37: 273–283. doi: 10.1152/advan.00066.201324292902
45. Yang CY, Best JA, Knell J, Yang E, Sheridan AD, et al. (2011) The transcriptional regulators Id2 and Id3 control the formation of distinct memory CD8+ T cell subsets. Nat Immunol12: 1221–1229. doi: 10.1038/ni.215822057289
46. Parish CR, (1971) Immune response to chemically modified flagellin. II. Evidence for a fundamental relationship between humoral and cell-mediated immunity. J Exp Med134: 21–47. 5558070
47. Parish CR, (1973) Immune response to chemically modified flagellin. IV. Further studies on the relationship between humoral and cell-mediated immunity. Cell Immunol6: 66–79. 4684525
48. Parish CR, Liew FY, (1972) Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin. J Exp Med135: 298–311. 5060292
49. Jagannathan P, Eccles-James I, Bowen K, Nankya F, Auma A, et al. (2014) IFNgamma/IL-10 co-producing cells dominate the CD4 response to malaria in highly exposed children. PLoS Pathog10: e1003864. doi: 10.1371/journal.ppat.100386424415936
50. Portugal S, Moebius J, Skinner J, Doumbo S, Doumtabe D, et al. (2014) Exposure-dependent control of malaria-induced inflammation in children. PLoS Pathog10: e1004079. doi: 10.1371/journal.ppat.100407924743880
51. Livingston BD, Alexander J, Crimi C, Oseroff C, Celis E, et al. (1999) Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J Immunol162: 3088–3095. 10072562
52. Engwerda C, Kaye P, (2000) Organ-specific immune responses associated with infectious disease. Immunology today21: 73–78. 10652464
53. Abubakar A, Ruiz-Postigo JA, Pita J, Lado M, Ben-Ismail R, et al. (2014) Visceral leishmaniasis outbreak in South Sudan 2009–2012: epidemiological assessment and impact of a multisectoral response. PLoS Negl Trop Dis8: e2720. doi: 10.1371/journal.pntd.000272024675573
54. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, et al. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med372: 2006–2017. doi: 10.1056/NEJMoa141442825891304
55. Butler NS, Moebius J, Pewe LL, Traore B, Doumbo OK, et al. (2012) Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection. Nat Immunol13: 188–195.
56. Zander RA, Obeng-Adjei N, Guthmiller JJ, Kulu DI, Li J, et al. (2015) PD-1 Co-inhibitory and OX40 Co-stimulatory Crosstalk Regulates Helper T Cell Differentiation and Anti-Plasmodium Humoral Immunity. Cell Host Microbe17: 628–641. doi: 10.1016/j.chom.2015.03.00725891357
57. Khalil EA, Weldegebreal T, Younis BM, Omollo R, Musa AM, et al. (2014) Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial. PLoS Negl Trop Dis8: e2613. doi: 10.1371/journal.pntd.000261324454970
58. Picado A, Ostyn B, Singh SP, Uranw S, Hasker E, et al. (2014) Risk factors for visceral leishmaniasis and asymptomatic Leishmania donovani infection in India and Nepal. PLoS One9: e87641. doi: 10.1371/journal.pone.008764124498159